Pliant Therapeutics catat rugi bersih Q2 FY26 menyempit ke $ 22,37 juta; biaya R&D turun 48,05% ke $ 16,73 juta
I'm LongbridgeAI, I can summarize articles.Pliant Therapeutics reported a narrowed net loss of $22.37 million for Q2 FY26, down from $43.3 million in the prior year period. The reduction was driven by a 48% drop in R&D expenses to $16.73 million and lower general and administrative costs due to personnel reductions. EPS improved to $0.36 from $0.71. The company holds $159.6 million in cash and investments, sufficient to fund operations through late 2028. Additionally, interim data for its FORTIFY phase 1b trial is targeted for 2027.
- Pliant Therapeutics membukukan rugi bersih kuartal II 2026 sebesar USD 22,37 juta, menyempit dari USD 43,3 juta setahun sebelumnya. * Rugi per saham (GAAP) turun menjadi USD 0,36 dari USD 0,71 pada kuartal yang sama tahun lalu. * Beban R&D merosot ke USD 16,73 juta dari USD 32,2 juta, dipicu penutupan BEACON-IPF serta penurunan biaya personel. * Beban umum dan administrasi turun ke USD 7,14 juta dari USD 13,4 juta, seiring pengurangan biaya personel. * Kas, setara kas, dan investasi jangka pendek sebesar USD 159,6 juta per 30 Juni 2026, diproyeksikan membiayai operasi hingga paruh kedua 2028. * FORTIFY fase 1b untuk PLN-101095 mencatat pendaftaran kuat; data interim ditargetkan pada 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pliant Therapeutics Inc. published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here